新华制药：获得磷酸奥司他韦干混悬剂药品注册证书

Core Viewpoint - The approval of the Oseltamivir Phosphate Dry Suspension by the National Medical Products Administration enhances the company's antiviral product line and overall competitiveness, although sales may be influenced by policy and market factors [1] Group 1: Product Approval - The company has received the drug registration certificate for Oseltamivir Phosphate Dry Suspension, classified as a non-prescription chemical drug (Category 3) [1] - The drug is indicated for the treatment of influenza A and B in patients aged 2 weeks and older, and for prevention in individuals aged 1 year and above [1] Group 2: Timeline and Market Impact - The company submitted the application materials in March 2024, which were accepted, and received approval in December 2025 [1] - The estimated sales of Oseltamivir-related formulations in Chinese public medical institutions for 2024 are approximately 5.9 billion [1] Group 3: Competitive Position - The approval enriches the company's antiviral drug product line, thereby enhancing its comprehensive competitiveness in the market [1] - However, the sales of the product may face uncertainties due to various factors such as policy and market conditions [1]